Related references
Note: Only part of the references are listed.Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
Jacquelyn A. Hank et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group
Andrew L. Gilman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
NKV Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer.
M Imai et al.
CANCER RESEARCH (2005)
Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy
ZC Neal et al.
CLINICAL CANCER RESEARCH (2004)
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients
DM King et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy
ZC Neal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation:: A Children's Cancer Group Study
MF Ozkaynak et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study
RC Seeger et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)